We continue to advance our pipeline of novel diagnostic products and generic products building upon our core competency in the areas of radiopharmaceuticals and lyophilized kits. Externally, we continually evaluate opportunities to acquire products or technologies that serve patients while strengthening our strategic position in the industry through strategic partnerships or in-licensing agreements.